Introduction
Why RBE (relative biological effectiveness) ?
• The RBE is defined as the ratio of doses to reach the same level of effect when comparing two modalities
• RBE for TCP could potentially deduced from tumor control data • RBE for NTCP is difficult to assess based on clinical data because photons generally deliver a more uniform dose to critical structures and the probability of radiation damage for a specified dose is sensitive to the volume of normal tissues irradiated • The majority of laboratory data are on RBE for cell survival in vitro "Repair kinetics in HR-deficient cells were significantly delayed after proton irradiation, with elevated amounts of residual gH2AX foci" RBE for cell survival -Endpoint dependency
RBE relevant for NTCP: Effect of interest (organ level):
• early effects such as erythema • late effects such as lung fibrosis, lung function, spinal cord injury, or necrosis Typically measured other than cell survival (cellular level):
• 
RBE depends on LET
 RBE seems to be higher for tissues with a low a/b ratio (mainly OAR)  RBE values for endpoints other than cell survival are less well known.  The RBE for normal tissue response is unclear RBE depends on a/b  RBE increases with decreasing dose  Indicates higher RBE for OAR  Measurements (in vitro and in vivo) typically do not provide high resolution below 2 Gy Scaling of LET x dose such that RBE = 1.1 in center of 5cm SOBP Biological treatment planning using physics information SUMMARY  Proton therapy uses a generic RBE of 1.1 because of substantial uncertainties in RBE as a function of dose, endpoint and LET  The RBE is potentially higher towards the distal end of an SOBP and for low α/β.  The relevance of endpoints other than cell survival for defining clinical RBEs is unclear.  For a given dose and organ, the RBE dependency on LET is monotone (reasonably linear)  There is no evidence (yet) for a correlation between LET and toxicity or recurrence  RBE/LET optimization may improve treatment outcome  Inter-patient variability (biomarkers?) is not well understood
